Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy

The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/re...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Rakesh, Maier, Harald J., Zhang, Jie, Lim, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294746/
https://www.ncbi.nlm.nih.gov/pubmed/37185251
http://dx.doi.org/10.1080/21645515.2023.2210046
_version_ 1785063256509906944
author Awasthi, Rakesh
Maier, Harald J.
Zhang, Jie
Lim, Stephen
author_facet Awasthi, Rakesh
Maier, Harald J.
Zhang, Jie
Lim, Stephen
author_sort Awasthi, Rakesh
collection PubMed
description The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.
format Online
Article
Text
id pubmed-10294746
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102947462023-06-28 Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy Awasthi, Rakesh Maier, Harald J. Zhang, Jie Lim, Stephen Hum Vaccin Immunother Immunotherapy - Cancer The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations. Taylor & Francis 2023-05-15 /pmc/articles/PMC10294746/ /pubmed/37185251 http://dx.doi.org/10.1080/21645515.2023.2210046 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Immunotherapy - Cancer
Awasthi, Rakesh
Maier, Harald J.
Zhang, Jie
Lim, Stephen
Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
title Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
title_full Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
title_fullStr Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
title_full_unstemmed Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
title_short Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
title_sort kymriah® (tisagenlecleucel) – an overview of the clinical development journey of the first approved car-t therapy
topic Immunotherapy - Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294746/
https://www.ncbi.nlm.nih.gov/pubmed/37185251
http://dx.doi.org/10.1080/21645515.2023.2210046
work_keys_str_mv AT awasthirakesh kymriahtisagenlecleucelanoverviewoftheclinicaldevelopmentjourneyofthefirstapprovedcarttherapy
AT maierharaldj kymriahtisagenlecleucelanoverviewoftheclinicaldevelopmentjourneyofthefirstapprovedcarttherapy
AT zhangjie kymriahtisagenlecleucelanoverviewoftheclinicaldevelopmentjourneyofthefirstapprovedcarttherapy
AT limstephen kymriahtisagenlecleucelanoverviewoftheclinicaldevelopmentjourneyofthefirstapprovedcarttherapy

Ejemplares similares